Androgen/androgen receptor (AR) signaling is known to be a significant driver of prostate cancer progression, therefore androgen-deprivation therapy (ADT)—with or without anti-androgens—is often used as a standard form of care for patients with advanced and metastatic prostate cancer [3,4]. Here, AR is linked to prostate cancer.